Results - Now Published - From Phase 2 Myelin Repair Trial in Relapsing National Multiple Sclerosis Society Help to Direct Future Studies Underway
July 09, 2019
July 09, 2019
NEW YORK, July 9 -- The National Multiple Sclerosis Society issued the following news:
Details of previously announced results have been published from a Phase 2 clinical trial of anti-LINGO (opicinumab), an experimental approach to repair myelin, the nerve-insulating coating damaged in multiple sclerosis. The trial, known as the SYNERGY study, did not meet its primary endpoint of improving measures of physical function (including walking, upper limb coordination), cognitive functio . . .
Details of previously announced results have been published from a Phase 2 clinical trial of anti-LINGO (opicinumab), an experimental approach to repair myelin, the nerve-insulating coating damaged in multiple sclerosis. The trial, known as the SYNERGY study, did not meet its primary endpoint of improving measures of physical function (including walking, upper limb coordination), cognitive functio . . .